Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia

Huck Joo Tan, Mohd Rizal Abdul Manaf, Mohamed Yusoff Rosmadi, Khean Lee Goh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background and Aim: The role of Helicobacter pylori (HP) in non-ulcer dyspepsia is debatable. Eradicating HP will help a small group of non-ulcer dyspeptic patients. However, it is unclear which subgroup of patients will benefit from eradication therapy. The aim of the present study was to compare the cagA and cagE status, as well as vacA genotypes, of HP in non-ulcer dyspeptic patients who responded successfully to eradication therapy compared with those patients who did not. Methods: Consecutive patients with moderate to severe (Likert 2 or 3) non-ulcer dyspepsia with HP were recruited prospectively. Gastric biopsies were taken, DNA extracted and polymerase chain reaction performed to determine the cagA and cagE status and vacA alleles. Eradication therapy was offered until HP was eradicated successfully. The HP status was checked 1 month after eradication therapy using the [13C]-urea breath test. All patients were assessed by one interviewer using Gastrointestinal Symptom Rating Scale (GSRS), a four-point Likert scale, and SF-36 for quality of life over 12 months. Treatment success was defined as minimal or no symptoms (Likert 1 or 0). The cagA, cagE and vacA status was blinded to the investigators until completion of the study. Results: Seventy-three patients (36 males, 37 females) were recruited to the study. The mean ± SD patient age was 53.38 ± 12.09 years. When the 36 patients who improved (group A) were compared with the 37 (group B) who did not, no significant difference was found in the cagE positive rate (55.6 vs 43.2%, respectively; P = 0.638), cagA positive rate (83.1 vs 73.0%, respectively; P = 0.247), vacA m1 versus m2 subtype (84.0 vs 55.6%, respectively; P = 0.472) or vacA s1a versus s1c (39.4 vs 57.1%, respectively; P = 0.166). There was also no significant difference noted in the SF-36 scores between the two groups after the conclusion of eradication therapy. Conclusions: Stratification of HP genotypes and virulence factor has no significant impact on the treatment success of non-ulcer dyspepsia.

Original languageEnglish
Pages (from-to)110-115
Number of pages6
JournalJournal of Gastroenterology and Hepatology (Australia)
Volume21
Issue number1 PART1
DOIs
Publication statusPublished - 2006

Fingerprint

Dyspepsia
Virulence Factors
Helicobacter pylori
Genotype
Therapeutics
Breath Tests
DNA-Directed DNA Polymerase
Urea
Stomach
Alleles
Quality of Life
Research Personnel
Interviews
Biopsy
Polymerase Chain Reaction

Keywords

  • Helicobacter
  • Non-ulcer dyspepsia
  • Virulence factors

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology

Cite this

Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia. / Tan, Huck Joo; Abdul Manaf, Mohd Rizal; Rosmadi, Mohamed Yusoff; Goh, Khean Lee.

In: Journal of Gastroenterology and Hepatology (Australia), Vol. 21, No. 1 PART1, 2006, p. 110-115.

Research output: Contribution to journalArticle

Tan, Huck Joo ; Abdul Manaf, Mohd Rizal ; Rosmadi, Mohamed Yusoff ; Goh, Khean Lee. / Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia. In: Journal of Gastroenterology and Hepatology (Australia). 2006 ; Vol. 21, No. 1 PART1. pp. 110-115.
@article{a26c1c5284aa460682418b4cd45940ee,
title = "Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia",
abstract = "Background and Aim: The role of Helicobacter pylori (HP) in non-ulcer dyspepsia is debatable. Eradicating HP will help a small group of non-ulcer dyspeptic patients. However, it is unclear which subgroup of patients will benefit from eradication therapy. The aim of the present study was to compare the cagA and cagE status, as well as vacA genotypes, of HP in non-ulcer dyspeptic patients who responded successfully to eradication therapy compared with those patients who did not. Methods: Consecutive patients with moderate to severe (Likert 2 or 3) non-ulcer dyspepsia with HP were recruited prospectively. Gastric biopsies were taken, DNA extracted and polymerase chain reaction performed to determine the cagA and cagE status and vacA alleles. Eradication therapy was offered until HP was eradicated successfully. The HP status was checked 1 month after eradication therapy using the [13C]-urea breath test. All patients were assessed by one interviewer using Gastrointestinal Symptom Rating Scale (GSRS), a four-point Likert scale, and SF-36 for quality of life over 12 months. Treatment success was defined as minimal or no symptoms (Likert 1 or 0). The cagA, cagE and vacA status was blinded to the investigators until completion of the study. Results: Seventy-three patients (36 males, 37 females) were recruited to the study. The mean ± SD patient age was 53.38 ± 12.09 years. When the 36 patients who improved (group A) were compared with the 37 (group B) who did not, no significant difference was found in the cagE positive rate (55.6 vs 43.2{\%}, respectively; P = 0.638), cagA positive rate (83.1 vs 73.0{\%}, respectively; P = 0.247), vacA m1 versus m2 subtype (84.0 vs 55.6{\%}, respectively; P = 0.472) or vacA s1a versus s1c (39.4 vs 57.1{\%}, respectively; P = 0.166). There was also no significant difference noted in the SF-36 scores between the two groups after the conclusion of eradication therapy. Conclusions: Stratification of HP genotypes and virulence factor has no significant impact on the treatment success of non-ulcer dyspepsia.",
keywords = "Helicobacter, Non-ulcer dyspepsia, Virulence factors",
author = "Tan, {Huck Joo} and {Abdul Manaf}, {Mohd Rizal} and Rosmadi, {Mohamed Yusoff} and Goh, {Khean Lee}",
year = "2006",
doi = "10.1111/j.1440-1746.2005.04063.x",
language = "English",
volume = "21",
pages = "110--115",
journal = "Journal of Gastroenterology and Hepatology (Australia)",
issn = "0815-9319",
publisher = "Wiley-Blackwell",
number = "1 PART1",

}

TY - JOUR

T1 - Role of Helicobacter pylori virulence factor and genotypes in non-ulcer dyspepsia

AU - Tan, Huck Joo

AU - Abdul Manaf, Mohd Rizal

AU - Rosmadi, Mohamed Yusoff

AU - Goh, Khean Lee

PY - 2006

Y1 - 2006

N2 - Background and Aim: The role of Helicobacter pylori (HP) in non-ulcer dyspepsia is debatable. Eradicating HP will help a small group of non-ulcer dyspeptic patients. However, it is unclear which subgroup of patients will benefit from eradication therapy. The aim of the present study was to compare the cagA and cagE status, as well as vacA genotypes, of HP in non-ulcer dyspeptic patients who responded successfully to eradication therapy compared with those patients who did not. Methods: Consecutive patients with moderate to severe (Likert 2 or 3) non-ulcer dyspepsia with HP were recruited prospectively. Gastric biopsies were taken, DNA extracted and polymerase chain reaction performed to determine the cagA and cagE status and vacA alleles. Eradication therapy was offered until HP was eradicated successfully. The HP status was checked 1 month after eradication therapy using the [13C]-urea breath test. All patients were assessed by one interviewer using Gastrointestinal Symptom Rating Scale (GSRS), a four-point Likert scale, and SF-36 for quality of life over 12 months. Treatment success was defined as minimal or no symptoms (Likert 1 or 0). The cagA, cagE and vacA status was blinded to the investigators until completion of the study. Results: Seventy-three patients (36 males, 37 females) were recruited to the study. The mean ± SD patient age was 53.38 ± 12.09 years. When the 36 patients who improved (group A) were compared with the 37 (group B) who did not, no significant difference was found in the cagE positive rate (55.6 vs 43.2%, respectively; P = 0.638), cagA positive rate (83.1 vs 73.0%, respectively; P = 0.247), vacA m1 versus m2 subtype (84.0 vs 55.6%, respectively; P = 0.472) or vacA s1a versus s1c (39.4 vs 57.1%, respectively; P = 0.166). There was also no significant difference noted in the SF-36 scores between the two groups after the conclusion of eradication therapy. Conclusions: Stratification of HP genotypes and virulence factor has no significant impact on the treatment success of non-ulcer dyspepsia.

AB - Background and Aim: The role of Helicobacter pylori (HP) in non-ulcer dyspepsia is debatable. Eradicating HP will help a small group of non-ulcer dyspeptic patients. However, it is unclear which subgroup of patients will benefit from eradication therapy. The aim of the present study was to compare the cagA and cagE status, as well as vacA genotypes, of HP in non-ulcer dyspeptic patients who responded successfully to eradication therapy compared with those patients who did not. Methods: Consecutive patients with moderate to severe (Likert 2 or 3) non-ulcer dyspepsia with HP were recruited prospectively. Gastric biopsies were taken, DNA extracted and polymerase chain reaction performed to determine the cagA and cagE status and vacA alleles. Eradication therapy was offered until HP was eradicated successfully. The HP status was checked 1 month after eradication therapy using the [13C]-urea breath test. All patients were assessed by one interviewer using Gastrointestinal Symptom Rating Scale (GSRS), a four-point Likert scale, and SF-36 for quality of life over 12 months. Treatment success was defined as minimal or no symptoms (Likert 1 or 0). The cagA, cagE and vacA status was blinded to the investigators until completion of the study. Results: Seventy-three patients (36 males, 37 females) were recruited to the study. The mean ± SD patient age was 53.38 ± 12.09 years. When the 36 patients who improved (group A) were compared with the 37 (group B) who did not, no significant difference was found in the cagE positive rate (55.6 vs 43.2%, respectively; P = 0.638), cagA positive rate (83.1 vs 73.0%, respectively; P = 0.247), vacA m1 versus m2 subtype (84.0 vs 55.6%, respectively; P = 0.472) or vacA s1a versus s1c (39.4 vs 57.1%, respectively; P = 0.166). There was also no significant difference noted in the SF-36 scores between the two groups after the conclusion of eradication therapy. Conclusions: Stratification of HP genotypes and virulence factor has no significant impact on the treatment success of non-ulcer dyspepsia.

KW - Helicobacter

KW - Non-ulcer dyspepsia

KW - Virulence factors

UR - http://www.scopus.com/inward/record.url?scp=33645227091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645227091&partnerID=8YFLogxK

U2 - 10.1111/j.1440-1746.2005.04063.x

DO - 10.1111/j.1440-1746.2005.04063.x

M3 - Article

VL - 21

SP - 110

EP - 115

JO - Journal of Gastroenterology and Hepatology (Australia)

JF - Journal of Gastroenterology and Hepatology (Australia)

SN - 0815-9319

IS - 1 PART1

ER -